{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:43:20Z","timestamp":1792478600096,"version":"4.5.0"},"reference-count":45,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15871","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:09:04Z","timestamp":1789729744000},"page":"1-16","source":"Crossref","is-referenced-by-count":0,"title":["Methyltransferase\u2011like 7B promotes M2\u2011like macrophage polarization in lung adenocarcinoma via upregulating human epidermal growth factor receptor 3 expression and secretion"],"prefix":"10.3892","volume":"32","author":[{"given":"Sixiao","family":"He","sequence":"first","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518020, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong 518020, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chaozhou Central Hospital, Chaozhou, Guangdong 521000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Central Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College), Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518020, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Public Health, University of South China, Hengyang, Hunan 421001, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, University of South China, Hengyang, Hunan 421001, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Cui","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518020, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zou","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518020, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"key20261020093240_b1-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: A population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"key20261020093240_b2-ol-32-5-15871","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20261020093240_b3-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"key20261020093240_b4-ol-32-5-15871","first-page":"387","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"key20261020093240_b5-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20261020093240_b6-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"key20261020093240_b7-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mco2.105","article-title":"Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy","volume":"2","author":"Cheng","year":"2021","journal-title":"MedComm (2020)"},{"key":"key20261020093240_b8-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"key20261020093240_b9-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","article-title":"Deciphering the performance of macrophages in tumour microenvironment: A call for precision immunotherapy","volume":"17","author":"Toledo","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20261020093240_b10-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"key20261020093240_b11-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20261020093240_b12-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","article-title":"Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion","volume":"58","author":"Waibl Polania","year":"2025","journal-title":"Immunity"},{"key":"key20261020093240_b13-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.immuni.2023.10.010","article-title":"Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis","volume":"56","author":"Do","year":"2023","journal-title":"Immunity"},{"key":"key20261020093240_b14-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"key20261020093240_b15-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20261020093240_b16-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-023-01477-7","article-title":"Methyltransferase-like proteins in cancer biology and potential therapeutic targeting","volume":"16","author":"Qi","year":"2023","journal-title":"J Hematol Oncol"},{"key":"key20261020093240_b17-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fphar.2020.00178","article-title":"METTL7B Is required for cancer cell proliferation and tumorigenesis in non-small cell lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol"},{"key":"key20261020093240_b18-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-022-01519-7","article-title":"Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma","volume":"21","author":"Song","year":"2022","journal-title":"Mol Cancer"},{"key":"key20261020093240_b19-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20261020093240_b20-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res"},{"key":"key20261020093240_b21-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2009.04.025","article-title":"Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment","volume":"137","author":"Jura","year":"2009","journal-title":"Cell"},{"key":"key20261020093240_b22-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20261020093240_b23-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-Targeting patritumab deruxtecan in EGFR-Mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20261020093240_b24-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1128\/mcb.14.6.3550-3558.1994","article-title":"ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor","volume":"14","author":"Soltoff","year":"1994","journal-title":"Mol Cell Biol"},{"key":"key20261020093240_b25-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"key20261020093240_b26-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"key20261020093240_b27-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol Res"},{"key":"key20261020093240_b28-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-20-4465","article-title":"Thirty years of HER3: From basic biology to therapeutic interventions","volume":"27","author":"Haikala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20261020093240_b29-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"key20261020093240_b30-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"22369","DOI":"10.1073\/pnas.0908787106","article-title":"Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20261020093240_b31-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"20462","DOI":"10.1074\/jbc.M116.750182","article-title":"Activation of epidermal growth factor receptor in macrophages mediates feedback inhibition of M2 polarization and gastrointestinal tumor cell growth","volume":"291","author":"Zhao","year":"2016","journal-title":"J Biol Chem"},{"key":"key20261020093240_b32-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"key20261020093240_b33-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20261020093240_b34-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.gendis.2024.101354","article-title":"HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway","volume":"12","author":"Desai","year":"2024","journal-title":"Genes Dis"},{"key":"key20261020093240_b35-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.gendis.2022.11.003","article-title":"PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain","volume":"10","author":"Li","year":"2022","journal-title":"Genes Dis"},{"key":"key20261020093240_b36-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/s12967-026-07934-4","article-title":"HER3 beyond the canonical paradigm: A versatile signaling hub in oncogenesis and therapeutic resistance","volume":"24","author":"Li","year":"2026","journal-title":"J Transl Med"},{"key":"key20261020093240_b37-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"key":"key20261020093240_b38-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(25)00465-6","article-title":"Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): A multicentre, single-arm, phase 2 trial","volume":"26","author":"Fuereder","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20261020093240_b39-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1758835919833519","DOI":"10.1177\/1758835919833519","article-title":"HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance","volume":"11","author":"Pernas","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"key20261020093240_b40-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key20261020093240_b41-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/cancers17101703","article-title":"ADAM proteases in cancer: Biological roles, therapeutic challenges, and emerging opportunities","volume":"17","author":"Arora","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20261020093240_b42-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.7150\/ijbs.127108","article-title":"Oligodendrocyte-secreted ERBB3 mediates the competitive uptake of copper ions by tumor cells to promote brain metastasis in lung cancer","volume":"22","author":"Yang","year":"2026","journal-title":"Int J Biol Sci"},{"key":"key20261020093240_b43-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"e155296","DOI":"10.1172\/jci.insight.155296","article-title":"ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion","volume":"7","author":"Gnosa","year":"2022","journal-title":"JCI insight"},{"key":"key20261020093240_b44-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1038\/sj.onc.1201866","article-title":"Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues","volume":"16","author":"Lee","year":"1998","journal-title":"Oncogene"},{"key":"key20261020093240_b45-ol-32-5-15871","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","article-title":"Roles of METTL3 in cancer: Mechanisms and therapeutic targeting","volume":"13","author":"Zeng","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:32:50Z","timestamp":1792477970000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15871","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}